GenStar to resume hemophilia Phase I

GNT said the FDA notified the company that it may proceed with Phase I testing of Maximum Adenovirus Factor VIII (MAX-AD FVIII) gene therapy to treat hemophilia A. The U.S. Phase I trial previously wa...